Dimitri Bennett

Dimitri Bennett

Auto-generated profile, based on publicly available information

Dimitri Bennett

Takeda Development Center Americas, Inc. Cambridge Massachusetts USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Gastroenterology
Verified
Journal Article
Open access
PDF file
YYYizhou Ye
Yizhou Ye
YYYu Yin
Yu Yin
SHSusanna Y. Huh
Susanna Y. Huh
CACristina Almansa
Cristina Almansa
DBDimitri Bennett
Dimitri Bennett
MCMichael Camilleri
Michael Camilleri
Background & Aims Although gastroparesis carries a considerable health care and patient burden, associated epidemiological data are limited. To provide new real-world evidence for gastroparesis, we estimated disease prevalence, and investigated patient demographics and disease etiology in a large US claims database. Methods This retrospective, cross-sectional analysis used de-identified, longitudinal patient-level enrollment and billing data for adults from the Optum Clinformatics Data Mart database, a large US national administrative health insurance claims database. Prevalence was age-, sex-, and geographical region–standardized using the 2018 US census. Descriptive analyses of demographic and clinical variables and underlying disease etiologies were performed. Results The overall standardized prevalence of gastroparesis was 267.7 (95% confidence interval [CI] 264.8–270.7) per 100,000 US adults, whereas prevalence of “definite” gastroparesis (individuals diagnosed within 3 months of gastric emptying scintigraphy testing with persistent symptoms for more than 3 months) was 21.5 (95% CI 20.6–22.4) per 100,000 persons. Patients with gastroparesis had an overall Charlson Comorbidity Index score of 4.2, indicating substantial comorbidity burden. The most frequently documented comorbidities were chronic pulmonary disease (46.4%), diabetes with chronic complication (37.3%), and peripheral vascular disease (30.4%). Patients most commonly had a diabetic etiology (57.4%; type 1, 5.7% and type 2, 51.7%), followed by postsurgical (15.0%), drug-induced (11.8%), and idiopathic (11.3%) etiologies. Conclusions New evidence is provided regarding the prevalence, patient demographics, and etiology of gastroparesis in the US general population. Wider availability of reliable objective gastric emptying measures and further education of medical professionals in recognizing and diagnosing gastroparesis would benefit future studies and improve understanding of disease epidemiology.

9 December 2020 in BMJ Evidence-Based Medicine
Verified
Journal Article
Open access
PDF file
GSGrammati Sarri
Grammati Sarri
EPElisabetta Patorno
Elisabetta Patorno
HYHongbo Yuan
Hongbo Yuan
JGJianfei (Jeff) Guo
Jianfei (Jeff) Guo
DBDimitri Bennett
Dimitri Bennett
TDThomas P. Debray
Thomas P. Debray
Introduction: High-quality randomised controlled trials (RCTs) provide the most reliable evidence on the comparative efficacy of new medicines. However, non-randomised studies (NRS) are increasingly recognised as a source of insights into the real-world performance of novel therapeutic products, particularly when traditional RCTs are impractical or lack generalisability. This means there is a growing need for synthesising evidence from RCTs and NRS in healthcare decision making, particularly given recent developments such as innovative study designs, digital technologies and linked databases across countries. Crucially, however, no formal framework exists to guide the integration of these data types. Objectives and Methods: To address this gap, we used a mixed methods approach (review of existing guidance, methodological papers, Delphi survey) to develop guidance for researchers and healthcare decision-makers on when and how to best combine evidence from NRS and RCTs to improve transparency and build confidence in the resulting summary effect estimates. Results: Our framework comprises seven steps on guiding the integration and interpretation of evidence from NRS and RCTs and we offer recommendations on the most appropriate statistical approaches based on three main analytical scenarios in healthcare decision making (specifically, ‘high-bar evidence’ when RCTs are the preferred source of evidence, ‘medium,’ and ‘low’ when NRS is the main source of inference). Conclusion: Our framework augments existing guidance on assessing the quality of NRS and their compatibility with RCTs for evidence synthesis, while also highlighting potential challenges in implementing it. This manuscript received endorsement from the International Society for Pharmacoepidemiology.

26 October 2019 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
GAGert Van Assche
Gert Van Assche
ITIgnacio Tagarro
Ignacio Tagarro
MDMary Carmen Diez
Mary Carmen Diez
MRMarie Paule Richard
Marie Paule Richard
JPJulián Panés
Julián Panés
Introduction Despite the fact that perianal fistulas are associated with significant morbidity and impaired quality of life, their prevalence in Europe is unknown. The aim of this study was to estimate the prevalence of perianal fistulas in Europe, overall and according to etiology. Methods Two independent literature reviews were performed using different search strategies to maximize the identification of potentially relevant studies. Data from relevant articles were used to estimate the prevalence of perianal fistulas in Europe. The robustness of the estimate was evaluated using data from a large population-based database from the UK. Results A total of 26 studies provided epidemiological data on perianal fistulas, of which 16 provided suitable data to estimate the prevalence. Estimations using these data yielded a total prevalence of 1.69 per 10,000 population. Cryptoglandular infection and Crohn’s disease (CD) were the predominant etiologies, with prevalence rates at 0.86 and 0.76 per 10,000 population, respectively. Comparison of prevalence data from the UK population-based database with the European population resulted in a standardized prevalence estimate of all perianal fistulas of 1.83 per 10,000 population, confirming the robustness of the literature-based estimate. Conclusion Although in terms of incidence cryptoglandular fistulas were clearly predominant, the prevalence of fistulas in CD and cryptoglandular infection appeared more balanced. This is due to the longer duration and higher frequency of relapses of fistulas in CD. The estimated prevalence implies that perianal fistulas meet the criteria to be considered as a rare condition in Europe (prevalence less than 5 per 10,000 population). Funding This study was funded by Takeda Pharmaceutical U.S.A., Inc. and TiGenix SAU.

13 February 2019 in JGH Open
Verified
Journal Article
Open access
PDF file
RCRachele Ciccocioppo
Rachele Ciccocioppo
CKCatherine Marie Klersy
Catherine Marie Klersy
DLDaniel A Leffler
Daniel A Leffler
RRRaquel Rogers
Raquel Rogers
DBDimitri Bennett
Dimitri Bennett
GCGino Roberto Corazza
Gino Roberto Corazza
Perianal fistulas in Crohn's disease (CD) represent a highly debilitating and difficult‐to‐treat condition. Given emerging supportive evidence, we conducted a systematic review and meta‐analysis of all trials/observational studies to establish the safety and efficacy of local injections of mesenchymal stem cells (MSCs). The PRISMA‐P statement was applied for planning and reporting, and MEDLINE, EMBASE, Web of Science, Cochrane, CINAHL, ClinicalTrials.gov database, and ECCO 2017 proceedings were searched for published observational studies and one‐arm and randomized clinical trials (RCTs). Safety was assessed in terms of acute local/systemic events, long‐term events, and relatedness with MSC treatment. Efficacy was evaluated in terms of external and/or radiological closure of fistula tracks. After a review of 211 citations, 23 studies, including 696 participants, were evaluated. Four were RCTs with a total of 483 patients. Overall, fistula closure occurred in 80% of MSC‐treated patients. In RCTs, this rate was 64% in the MSC arm and 37% in the control arm (relative risk (RR) = 1.54). Radiological response occurred in 83% of MSC‐treated patients. Treatment‐related adverse events occurred in 1% of MSC‐treated patients, with severe treatment‐related adverse events reaching 0% over a median follow‐up of 6 months. In RCTs, treatment‐related adverse events occurred in 13% in the MSC arm and 24% in the control arm (RR = 0.65). The relapse rate was 0. These results suggest that a local MSC injection is safe and efficacious. Further clinical trials with standardized end‐points are required to ensure the timely implementation of this new therapy in the management of perianal CD.

5 July 2022 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
RWRichard Wyss
Richard Wyss
CYChen Yanover
Chen Yanover
TETal El‐Hay
Tal El‐Hay
DBDimitri Bennett
Dimitri Bennett
RPRobert W. Platt
Robert W. Platt
KLKueiyu Joshua Lin
Kueiyu Joshua Lin
Purpose: Supplementing investigator‐specified variables with large numbers of empirically identified features that collectively serve as ‘proxies’ for unspecified or unmeasured factors can often improve confounding control in studies utilizing administrative healthcare databases. Consequently, there has been a recent focus on the development of data‐driven methods for high‐dimensional proxy confounder adjustment in pharmacoepidemiologic research. In this paper, we survey current approaches and recent advancements for high‐dimensional proxy confounder adjustment in healthcare database studies.Methods: We discuss considerations underpinning three areas for high‐dimensional proxy confounder adjustment: (1) feature generation—transforming raw data into covariates (or features) to be used for proxy adjustment; (2) covariate prioritization, selection, and adjustment; and (3) diagnostic assessment. We discuss challenges and avenues of future development within each area.Results: There is a large literature on methods for high‐dimensional confounder prioritization/selection, but relatively little has been written on best practices for feature generation and diagnostic assessment. Consequently, these areas have particular limitations and challenges.Conclusions: There is a growing body of evidence showing that machine‐learning algorithms for high‐dimensional proxy‐confounder adjustment can supplement investigator‐specified variables to improve confounding control compared to adjustment based on investigator‐specified variables alone. However, more research is needed on best practices for feature generation and diagnostic assessment when applying methods for high‐dimensional proxy confounder adjustment in pharmacoepidemiologic studies.

7 February 2023 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
DJDaniela R. Junqueira
Daniela R. Junqueira
DBDimitri Bennett
Dimitri Bennett
SHSusanna Y. Huh
Susanna Y. Huh
KFKyle Fahrbach
Kyle Fahrbach
BNBinod Neupane
Binod Neupane
MBMarissa Betts
Marissa Betts
Background Dopamine antagonists are the main pharmacological options to treat gastroparesis. The aim of this study was to conduct a systematic literature review (SLR) to evaluate the profile of adverse events (AEs) of dopamine antagonists used in the treatment of children and adults with gastroparesis. Methods We searched EMBASE and MEDLINE up to March 25, 2021, for relevant clinical trials and observational studies. We conducted a proportional meta-analysis to estimate the pooled occurrence of AEs (%), with 95% confidence interval (CI), from arm-level data across studies and the comparative occurrence of AEs from placebo-controlled clinical trials (odds ratio [OR] with 95% CI). Results We identified 28 studies assessing AEs experienced by patients treated for gastroparesis with domperidone and metoclopramide; 22 studies contributed data to the meta-analyses. Cardiovascular, neurological, and endocrine AEs were commonly observed, with point incidences varying from 1 to > 50%. Clinically important AEs, such as QTc prolongation, occurred in 5% of patients treated with domperidone (95% CI: 3.32–8.62). Restlessness, an extrapyramidal AE, occurred in 15% of patients (95% CI: 7.48–26.61) treated with metoclopramide, with a 7-fold increase compared with patients receiving placebo (OR: 7.72; 95% CI: 1.27–47.05). Variation in terminology to describe extrapyramidal events precluded further pooled analyses. Additional meta-analyses were not feasible due to discrepancies in the assessment and reporting of the AEs. Conclusions The evidence confirms concerns of cardiovascular, extrapyramidal, and endocrine AEs in patients with gastroparesis treated with domperidone and metoclopramide. Imprecise AE reporting limits firm interpretation and conclusions. Registration PROSPERO international prospective register of systematic reviews (registration number: CRD42021248888).